Menopur (Menotrophin)

Menotropin contains both follicle‑stimulating hormone (FSH) and luteinizing hormone (LH) activity. By binding to FSH receptors on granulosa cells and LH receptors on theca cells, it stimulates follicular growth, estrogen production, and final oocyte maturation, thereby facilitating ovulation and improving the response to assisted reproductive procedures.

The dose of Menopur is individualized. A qualified prescriber determines the amount and frequency based on the patient’s ovarian reserve, response to prior stimulation, and the specific protocol of the assisted reproductive programme. Patients should follow the prescribing clinician’s instructions precisely.

Menopur is intended for use before pregnancy to achieve conception. Its safety in established pregnancy has not been established, and it is not recommended for use during pregnancy. Limited data are available for breastfeeding; therefore, the medication should be avoided while nursing unless the prescriber decides the benefit outweighs potential risk.

To order Menopur, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including cold‑chain handling if required) and any necessary import documentation.

Menopur provides a combined FSH and LH activity in a single preparation, whereas some alternatives contain only FSH (e.g., follitropin alfa) and require separate LH supplementation. The combined formulation can simplify dosing and may be advantageous for patients who need both hormones for optimal follicular development, though clinical choice depends on individual response and physician preference.

Menopur should be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. Once reconstituted, the solution should be used within the time frame specified in the product label and stored under the same refrigerated conditions.

Menopur is supplied as a powder for solution for injection. After reconstitution with the appropriate diluent, it is administered by subcutaneous or intramuscular injection according to the prescriber’s instructions. The injection site is typically the abdomen or thigh, and patients are trained on proper aseptic technique.

The most serious risks include severe ovarian hyperstimulation syndrome (OHSS), which can cause rapid weight gain, abdominal pain, and fluid accumulation, and thromboembolic events such as blood clots. Early recognition of symptoms and close monitoring by a fertility specialist are essential to mitigate these risks.

Menopur should not be used in individuals with known hypersensitivity to menotropin or any of its excipients, in patients who are currently pregnant, or in those with uncontrolled endocrine disorders such as untreated thyroid disease. Caution is also advised for patients with ovarian cysts, severe ovarian failure, or a history of thromboembolic disease.